Yourgene Health PLC National Framework contract award (8092V)
19 April 2021 - 4:00PM
UK Regulatory
TIDMYGEN
RNS Number : 8092V
Yourgene Health PLC
19 April 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
National Framework contract award for Covid-19 testing products
and services
Yourgene successful in UK-wide National Microbiology Framework
(Lot 1)
Manchester, UK - 19 April 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that it has
been awarded a Framework Agreement under Public Health England's
("PHE") National Microbiology Framework for Lot 1 ( Diagnostic
Goods and Services) of the four-lot tender for it s Clarigene (R)
SARS-CoV-2 assay and Manchester-based COVID testing service .
PHE's National Microbiology Framework is appointing suppliers to
framework agreements for four lots. Lot 1 is the first to be
announced and covers the supply of in-vitro diagnostic medical
devices and associated services, including for the Company's
Clarigene(R) SARS-CoV-2 PCR assay and the associated clinical
laboratory testing services delivered through Yourgene Genomic
Services. The term of the Framework Agreement for Lot 1 (and for
each subsequent lot, if awarded) is for an initial two years with
options to extend by up to a further two years. Lot 1 is a GBP3bn
tender to be satisfied by multiple successful bidders.
Under the National Microbiology Framework, participating public
health authorities across the United Kingdom can use call-off
contracts to procure goods and testing services from Yourgene under
such lots as it is in receipt of a Framework Agreement, but there
is no guarantee that such contracts will be forthcoming, nor as to
the quantum of any potential call-off contracts may which
arise.
Lyn Rees, CEO of Yourgene commented:
"We welcome the opportunity to work with PHE and its sister
organisations across the NHS, DHSC and in Wales, Scotland and
Northern Ireland to offer our Clarigene(R) SARS-CoV-2 PCR assay,
and our accredited lab testing services, to contain Covid-19 in the
near-term and to participate in putting in place a robust testing
infrastructure post-pandemic. Yourgene considers that the
successful framework award, for which there was a competitive
tender process, lends significant credibility to the Clarigene(R)
product and to the Company's COVID testing services . More broadly,
we expect the award to support business development outside the
scope of this agreement with a growing network of commercial
partners, addressing privately funded testing in healthcare and
workplace settings."
This announcement contains inside information for the purposes
of UK Market Abuse Regulation . The Directors of the Company take
responsibility for this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391
303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKFBNKBKBOQD
(END) Dow Jones Newswires
April 19, 2021 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024